Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lopinavir

FDA-approved product (capsule, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Lopinavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Lopinavir reaches ≥40% AI-predicted activity against M. tuberculosis and MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lopinavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lopinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • LAAM-HAART PET Imaging

    NCT01935830 · start 2013-08

    Registered record
    Registry ID
    NCT01935830
    Conditions
    Healthy Volunteers
    Interventions
    [11c] LAAM; Ritonavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2015-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Intervention[11c] LAAM; Ritonavir; Efavirenz
    PhaseEarly phase 1
    Registry statusCompleted

  • Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

    NCT01601626 · start 2013-07-13

    Registered record
    Registry ID
    NCT01601626
    Conditions
    HIV Infection; Tuberculosis
    Interventions
    Standard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid; Pyridoxine; Pyrazinamide; Ethambutol; Rifabutin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07-13
    Completion
    2017-06-28
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis
    InterventionStandard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid +5 more
    PhasePhase 2
    Registry statusTerminated

  • Effects of Intensive cART During Acute/Early HIV Infection

    NCT01154673 · start 2011-11

    Registered record
    Registry ID
    NCT01154673
    Conditions
    Acute HIV Infection
    Interventions
    raltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute HIV Infection
    Interventionraltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression

    NCT01471821 · start 2011-10

    Registered record
    Registry ID
    NCT01471821
    Conditions
    HIV Infection
    Interventions
    antiretroviral treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2014-04
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Interventionantiretroviral treatment
    PhasePhase 4
    Registry statusCompleted

  • Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)

    NCT01383005 · start 2011-06

    Registered record
    Registry ID
    NCT01383005
    Conditions
    Human Immunodeficiency Virus Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-06
    Completion
    2011-12
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

    NCT01061151 · start 2011-03-01

    Registered record
    Registry ID
    NCT01061151
    Conditions
    HIV Infections
    Interventions
    Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV); Lopinavir-ritonavir (LPV-RTV); Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Nevirapine (NVP): Infant short-course; Nevirapine (NVP): Infant extended; No Intervention; Discontinue triple ARVs; Continue triple ARVs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03-01
    Completion
    2016-09-30
    Enrolment
    3,747

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV) +7 more
    PhasePhase 3
    Registry statusCompleted

  • Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

    NCT01189695 · start 2010-12

    Registered record
    Registry ID
    NCT01189695
    Conditions
    HIV; AIDS; Lopinavir; Treatment Failure
    Interventions
    Ritonavir-boosted lopinavir; optimized background regimens (OBRs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-12
    Completion
    2013-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Lopinavir; Treatment Failure
    InterventionRitonavir-boosted lopinavir; optimized background regimens (OBRs)
    PhasePhase 4
    Registry statusCompleted

  • Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

    NCT02097381 · start 2010-04

    Registered record
    Registry ID
    NCT02097381
    Conditions
    HIV Infection
    Interventions
    Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2014-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionTenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
    PhaseNot applicable
    Registry statusUnknown

  • Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

    NCT00949234 · start 2010-03

    Registered record
    Registry ID
    NCT00949234
    Conditions
    HIV Prevention; HIV Infections
    Interventions
    tenofovir + emtricitabine, lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-08
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention; HIV Infections
    Interventiontenofovir + emtricitabine, lopinavir/ritonavir
    PhasePhase 2
    Registry statusCompleted

  • A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

    NCT00931463 · start 2009-09

    Registered record
    Registry ID
    NCT00931463
    Conditions
    HIV Infections
    Interventions
    raltegravir; 2N(t)RTI; Ritonavir-boosted lopinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-08
    Enrolment
    558

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionraltegravir; 2N(t)RTI; Ritonavir-boosted lopinavir
    PhasePhase 4
    Registry statusCompleted

  • HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

    NCT00978068 · start 2009-09

    Registered record
    Registry ID
    NCT00978068
    Conditions
    Malaria; HIV Infections
    Interventions
    Lopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; HIV Infections
    InterventionLopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    PhasePhase 3
    Registry statusCompleted

  • A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

    NCT00827112 · start 2009-03

    Registered record
    Registry ID
    NCT00827112
    Conditions
    Human Immunodeficiency Virus-1
    Interventions
    maraviroc; maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2011-07
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus-1
    Interventionmaraviroc; maraviroc
    PhasePhase 2
    Registry statusCompleted

  • Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

    NCT00756730 · start 2008-09

    Registered record
    Registry ID
    NCT00756730
    Conditions
    HIV Infections
    Interventions
    ATV/r; DRV/r
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2011-06
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionATV/r; DRV/r
    PhasePhase 4
    Registry statusCompleted

  • TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.

    NCT00767117 · start 2008-09

    Registered record
    Registry ID
    NCT00767117
    Conditions
    HIV
    Interventions
    Etravirine; Lopinavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionEtravirine; Lopinavir; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Relationship Between HIV-1 Subtype and ARV Response

    NCT00585793 · start 2008-07

    Registered record
    Registry ID
    NCT00585793
    Conditions
    HIV Infections
    Interventions
    NRTI/NNRTI/ Kaletra
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-07
    Completion
    2010-02
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNRTI/NNRTI/ Kaletra
    PhaseNot recorded
    Registry statusCompleted